Skip to content
2000
Volume 11, Issue 3
  • ISSN: 2215-0838
  • E-ISSN: 2215-0846

Abstract

Psoriasis is a chronic skin condition characterized by the rapid buildup of skin cells, leading to thick, silvery scales and red, irritated, and dry patches. It It is an autoimmune skin condition that is incurable, non-contagious, and characterized by a relapsing-remitting course. that is incurable, non-contagious, and relapsing-remitting. Typically, a remission phase lasts one to twelve months. Psoriasis is caused by a number of cellular mechanisms, and it has been hypothesised that T lymphocytes, keratinocytes, allergen cells, Langerhans cells, natural killer cells, phagocytes, a number of Th1-type chemokines, in addition to growth factors like endothelial proliferation factor and keratinocytes growth factor, among others, are key players in the development of psoriasis. Numerous synthetic medicinal drugs have been documented to have the side effects of psoriasis. Due to the safety and accessibility, herbal medications may hold promise as possible anti-psoriatic molecules. Before creating a potential herbal drug, it is important to thoroughly examine the key players in the evolution of psoriasis, such as T-cell stimulation, transportation, and cytokine inhibition. The purpose of this review is to investigate how psoriasis spreads and becomes activated, as well as how certain medications might exacerbate the condition and how certain plant resources may be used to treat psoriasis. To create a potent, secure, and dependable treatment, more scientific research on these herbal resources is required.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ctm/10.2174/0122150838251874231011093514
2023-10-30
2026-01-03

  • From This Site

    /content/journals/ctm/10.2174/0122150838251874231011093514
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. OgawaK. OkadaY. The current landscape of psoriasis genetics in 2020.J. Dermatol. Sci.20209912810.1016/j.jdermsci.2020.05.008 32536600
     [Google Scholar]
  2. GhargeR. PhadatareS. ShindeS. ChogaleE. PatilS. PujareP. Psoriasis: Causes, Diagnosis and Management.Small20211534
     [Google Scholar]
  3. PradhanM. AlexanderA. SinghM.R. Understanding the prospective of nano-formulations towards the treatment of psoriasis.Biomed. Pharmacother.201810744746310.1016/j.biopha.2018.07.156 30103117
     [Google Scholar]
  4. TorsekarR. GautamM. Topical therapies in psoriasis.Indian Dermatol. Online J.20178423524510.4103/2229‑5178.209622 28761838
     [Google Scholar]
  5. ZangenehF.Z. ShooshtaryF.S. Psoriasis-Types, Causes and Medication.IntechOpen201310.5772/54728
     [Google Scholar]
  6. DamianiG. BragazziN.L. Karimkhani AksutC. The global, regional, and national burden of psoriasis: Results and insights from the global burden of disease 2019 study.Front. Med.2021874318010.3389/fmed.2021.743180 34977058
     [Google Scholar]
  7. ArmstrongA.W. ReadC. Pathophysiology, clinical presentation, and treatment of psoriasis.JAMA2020323191945196010.1001/jama.2020.4006 32427307
     [Google Scholar]
  8. JawadM.A. KadhimA.J. Psoriasis-cell mediated autoimmune disease: A review.J Pharm Qual Assur2021123306310
     [Google Scholar]
  9. BenlabsirC. RiyadM. SaikI.E.I. HLA-C genotyping reveals haplotype C*07 as a potential biomarker of late psoriasis onset in Moroccan Patients.Curr. Issues Mol. Biol.20234521012102310.3390/cimb45020066 36826011
     [Google Scholar]
  10. NevittG.J. HutchinsonP.E. Psoriasis in the community: Prevalence, severity and patients’ beliefs and attitudes towards the disease.Br. J. Dermatol.1996135453353710.1046/j.1365‑2133.1996.d01‑1035.x 8915141
     [Google Scholar]
  11. BoehnckeW.H. SchönM.P. Psoriasis.Lancet2015386999798399410.1016/S0140‑6736(14)61909‑7 26025581
     [Google Scholar]
  12. BasavarajK.H. NavyaM.A. RashmiR. RashmiR. Stress and quality of life in psoriasis: An update.Int. J. Dermatol.201150778379210.1111/j.1365‑4632.2010.04844.x 21699511
     [Google Scholar]
  13. KamiyaK. KishimotoM. SugaiJ. KomineM. OhtsukiM. Risk factors for the development of psoriasis.Int. J. Mol. Sci.20192018434710.3390/ijms20184347 31491865
     [Google Scholar]
  14. ZengJ. LuoS. HuangY. LuQ. Critical role of environmental factors in the pathogenesis of psoriasis.J. Dermatol.201744886387210.1111/1346‑8138.13806 28349593
     [Google Scholar]
  15. LeeE.B. WuK.K. LeeM.P. BhutaniT. WuJ.J. Psoriasis risk factors and triggers.Cutis20181025S1820 30566552
     [Google Scholar]
  16. DograS. DivyaKamat. Drug-induced psoriasis.Indian J. Rheumatol.2019143743
     [Google Scholar]
  17. GuptaR. DebbanehM.G. LiaoW. Genetic epidemiology of psoriasis.Curr. Dermatol. Rep.201431617810.1007/s13671‑013‑0066‑6 25580373
     [Google Scholar]
  18. JainA.K. RameshV. DasR.P. Current concepts in the pathogenesis of psoriasis.Indian J. Dermatol.200954171210.4103/0019‑5154.48977 20049260
     [Google Scholar]
  19. MehlisS.L. GordonK.B. The immunology of psoriasis and biologic immunotherapy.J. Am. Acad. Dermatol.2003492Suppl.445010.1016/S0190‑9622(03)01134‑4 12894125
     [Google Scholar]
  20. Di MeglioP. VillanovaF. NestleF.O. Psoriasis.Cold Spring Harb. Perspect. Med.201448a01535410.1101/cshperspect.a015354 25085957
     [Google Scholar]
  21. RendonA. SchäkelK. Psoriasis pathogenesis and treatment.Int. J. Mol. Sci.2019206147510.3390/ijms20061475 30909615
     [Google Scholar]
  22. McGregorJ.M. BarkerJ.N.W.N. RossE.L. MacDonaldD.M. Epidermal dendritic cells in psoriasis possess a phenotype associated with antigen presentation: In situ expression of β2-integrins.J. Am. Acad. Dermatol.199227338338810.1016/0190‑9622(92)70203‑R 1401271
     [Google Scholar]
  23. JoshiR. Immunopathogenesis of psoriasis.Indian J. Dermatol. Venereol. Leprol.20047011012 17642549
     [Google Scholar]
  24. LongoR. SarmientoR. FanelliM. CapaccettiB. GattusoD. GaspariniG. Anti-angiogenic therapy: Rationale, challenges and clinical studies.Angiogenesis20025423725610.1023/A:1024532022166 12906317
     [Google Scholar]
  25. CreamerD. SullivanD. BicknellR. BarkerJ. Angiogenesis in psoriasis.Angiogenesis20025423123610.1023/A:1024515517623 12906316
     [Google Scholar]
  26. LandeR. BottiE. JandusC. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis.Nat. Commun.201451562110.1038/ncomms6621 25470744
     [Google Scholar]
  27. KumarD. RajguruJ.P. MayaD. SuriP. BhardwajS. PatelN. Update on psoriasis: A review.J. Family Med. Prim. Care202091202410.4103/jfmpc.jfmpc_689_19 32110559
     [Google Scholar]
  28. JinY. YangS. ZhangF. Combined effects of HLA-Cw6 and cigarette smoking in psoriasis vulgaris: A hospital-based case-control study in China.J. Eur. Acad. Dermatol. Venereol.200923213213710.1111/j.1468‑3083.2008.02951.x 18702622
     [Google Scholar]
  29. FarkasÁ. KeményL. Alcohol, liver, systemic inflammation and skin: A focus on patients with psoriasis.Skin Pharmacol. Physiol.201326311912610.1159/000348865 23549156
     [Google Scholar]
  30. HøjgaardP. GlintborgB. HetlandM.L. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry.Ann. Rheum. Dis.201574122130213610.1136/annrheumdis‑2014‑205389 25063827
     [Google Scholar]
  31. PappK. GulliverW. LyndeC. PoulinY. AshkenasJ. Canadian Psoriasis Guidelines CommitteeCanadian guidelines for the management of plaque psoriasis: overview.J. Cutan. Med. Surg.201115421021910.2310/7750.2011.10066 21781627
     [Google Scholar]
  32. KimW.B. JeromeD. YeungJ. Diagnosis and management of psoriasis.Can. Fam. Physician2017634278285 28404701
     [Google Scholar]
  33. KhopkarU. NischalK.C. Dermoscope.Indian J. Dermatol. Venereol. Leprol.200571430030310.4103/0378‑6323.16633 16394450
     [Google Scholar]
  34. GubnerR. AugustS. GinsbergV. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis.Am. J. Med. Sci.1951221217618210.1097/00000441‑195102000‑00009 14799481
     [Google Scholar]
  35. CarreteroG. PuigL. DehesaL. Grupo de Psoriasis de la AEDV. Guidelines on the Use of Methotrexate in Psoriasis.Actas Dermosifiliogr.2010101760061310.1016/j.ad.2010.04.002
     [Google Scholar]
  36. CronsteinB.N. NaimeD. OstadE. The antiinflammatory effects of methotrexate are mediated by adenosine.Adv. Exp. Med. Biol.199537041141610.1007/978‑1‑4615‑2584‑4_89 7660940
     [Google Scholar]
  37. ElangoT. DayalanH. GnanarajP. MalligarjunanH. SubramanianS. Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients.Clin. Exp. Med.201414443143710.1007/s10238‑013‑0252‑7 23949337
     [Google Scholar]
  38. OgawaE. SatoY. MinagawaA. OkuyamaR. Pathogenesis of psoriasis and development of treatment.J. Dermatol.201845326427210.1111/1346‑8138.14139 29226422
     [Google Scholar]
  39. SchaferP. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.Biochem. Pharmacol.201283121583159010.1016/j.bcp.2012.01.001 22257911
     [Google Scholar]
  40. CravenN.M. GriffithsC.K.M. Topical retinoids and cutaneous biology.Clin. Exp. Dermatol.199621111010.1111/j.1365‑2230.1996.tb00001.x 8689759
     [Google Scholar]
  41. GudasL.J. Retinoids induce stem cell differentiation via epigenetic changes.Semin. Cell Dev. Biol.20132410-1270170510.1016/j.semcdb.2013.08.002 23973942
     [Google Scholar]
  42. SauratJ-H. Retinoids and psoriasis: Novel issues in retinoid pharmacology and implications for psoriasis treatment.J. Am. Acad. Dermatol.1999413S2S610.1016/S0190‑9622(99)70358‑0 10459139
     [Google Scholar]
  43. CarlbergC. Mechanisms of Nuclear Signalling by Vitamin D 3.E.J.B. Rev199523324310.1007/978‑3‑642‑85252‑7_16
     [Google Scholar]
  44. MattozziC. PaolinoG. RichettaA.G. CalvieriS. Psoriasis, vitamin D and the importance of the cutaneous barrier’s integrity: An update.J. Dermatol.201643550751410.1111/1346‑8138.13305 26971536
     [Google Scholar]
  45. BarreaL. SavanelliM.C. Di SommaC. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist.Rev. Endocr. Metab. Disord.201718219520510.1007/s11154‑017‑9411‑6 28176237
     [Google Scholar]
  46. TrémezayguesL. ReichrathJ. VitaminD. Vitamin D analogs in the treatment of psoriasis.Dermatoendocrinol20113318018610.4161/derm.17534 22110777
     [Google Scholar]
  47. KerkhofP.C.M. Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms.Br. J. Dermatol.1995132567568210.1111/j.1365‑2133.1995.tb00710.x 7772470
     [Google Scholar]
  48. PerezA. RaabR. ChenT.C. TurnerA. HolickM.F. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis.Br. J. Dermatol.1996134610701078 8763427
     [Google Scholar]
  49. KimH.J. LebwohlM.G. Biologics and Psoriasis.Dermatol. Clin.2019371293610.1016/j.det.2018.07.004 30466686
     [Google Scholar]
  50. PithadiaD.J. ReynoldsK.A. LeeE.B. LiaoW. WuJ.J. Tildrakizumab in the treatment of psoriasis: Latest evidence and place in therapy.Ther. Adv. Chronic Dis.201910204062231986565810.1177/2040622319865658 31448070
     [Google Scholar]
  51. RønholtK. IversenL. Old and new biological therapies for psoriasis.Int. J. Mol. Sci.20171811229710.3390/ijms18112297 29104241
     [Google Scholar]
  52. GordonK.B. FoleyP. KruegerJ.G. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.Lancet20213971027347548610.1016/S0140‑6736(21)00126‑4 33549192
     [Google Scholar]
  53. ZhangP. WuM.X. A clinical review of phototherapy for psoriasis.Lasers Med. Sci.201833117318010.1007/s10103‑017‑2360‑1 29067616
     [Google Scholar]
  54. JoeB. LokeshB.R. Effect of curcumin and capsaicin on arachidonic acid metabolism and lysosomal enzyme secretion by rat peritoneal macrophages.Lipids199732111173118010.1007/s11745‑997‑0151‑8 9397403
     [Google Scholar]
  55. BernsteinJ.E. ParishL.C. RapaportM. RosenbaumM.M. RoenigkH.H.Jr Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris.J. Am. Acad. Dermatol.198615350450710.1016/S0190‑9622(86)70201‑6 3760276
     [Google Scholar]
  56. EllisC.N. BerberianB. SulicaV.I. A double-blind evaluation of topical capsaicin in pruritic psoriasis.J. Am. Acad. Dermatol.199329343844210.1016/0190‑9622(93)70208‑B 7688774
     [Google Scholar]
  57. SyedT.A. AhmadS.A. HoltA.H. AhmadS.A. AhmadS.H. AfzalM. Management of psoriasis with Aloe vera extract in a hydrophilic cream: A placebo-controlled, double-blind study.Trop. Med. Int. Health19961450550910.1046/j.1365‑3156.1996.d01‑91.x 8765459
     [Google Scholar]
  58. KleinA.D. PenneysN.S. Aloe vera.J. Am. Acad. Dermatol.198818471472010.1016/S0190‑9622(88)70095‑X 3286692
     [Google Scholar]
  59. RobsonM.C. HeggersJ.P. HagstromW.J.Jr Myth, magic, witchcraft, or fact? Aloe vera revisited.J. Burn Care Rehabil.19823315416310.1097/00004630‑198205000‑00005
     [Google Scholar]
  60. ChoonhakarnC. BusaracomeP. SripanidkulchaiB. SarakarnP. A prospective, randomized clinical trial comparing topical aloe vera with 0.1% triamcinolone acetonide in mild to moderate plaque psoriasis.J. Eur. Acad. Dermatol. Venereol.201024216817210.1111/j.1468‑3083.2009.03377.x 19686327
     [Google Scholar]
  61. PaulsenE. KorsholmL. BrandrupF. A double-blind, placebo-controlled study of a commercial Aloe vera gel in the treatment of slight to moderate psoriasis vulgaris.J. Eur. Acad. Dermatol. Venereol.200519332633110.1111/j.1468‑3083.2004.01186.x 15857459
     [Google Scholar]
  62. DhanabalS.P. Priyanka DwarampudiL. MurugananthamN. VadivelanR. Evaluation of the antipsoriatic activity of Aloe vera leaf extract using a mouse tail model of psoriasis.Phytother. Res.201226461761910.1002/ptr.3589 21915932
     [Google Scholar]
  63. SabirS. ArsshadM. AsifS. ChaudhariS.K. An insight into medicinal and therapeutic potential of Silybum marianum (L.) Gaertn.Int. J. Biol. Sci.2014411104105
     [Google Scholar]
  64. BhucharS. KattaR. WolfJ. Complementary and alternative medicine in dermatology: An overview of selected modalities for the practicing dermatologist.Am. J. Clin. Dermatol.201213531131710.2165/11597560‑000000000‑00000 22668453
     [Google Scholar]
  65. KooJ. ArainS. Traditional Chinese medicine for the treatment of dermatologic disorders.Arch. Dermatol.1998134111388139310.1001/archderm.134.11.1388 9828872
     [Google Scholar]
  66. MurtiK. PanchalM.A. GajeraV. SolankiJ. Pharmacological properties of matricaria recutita: A review.Pharmacologia20123834835110.5567/pharmacologia.2012.348.351
     [Google Scholar]
  67. SafayhiH. SabierajJ. SailerE.R. AmmonH. Chamazulene: An antioxidant-type inhibitor of leukotriene B4 formation.Planta Med.199460541041310.1055/s‑2006‑959520 7997466
     [Google Scholar]
  68. CarsonC.F. AshtonL. DryL. SmithD.W. RileyT.V. Melaleuca alternifolia (tea tree) oil gel (6%) for the treatment of recurrent herpes labialis.J. Antimicrob. Chemother.200148345045110.1093/jac/48.3.450 11533019
     [Google Scholar]
  69. CarsonC.F. RileyT.V. CooksonB.D. Efficacy and safety of tea tree oil as a topical antimicrobial agent.J. Hosp. Infect.199840317517810.1016/S0195‑6701(98)90135‑9 9830588
     [Google Scholar]
  70. KohK.J. PearceA.L. MarshmanG. Finlay-JonesJ.J. HartP.H. Tea tree oil reduces histamine-induced skin inflammation.Br. J. Dermatol.200214761212121710.1046/j.1365‑2133.2002.05034.x 12452873
     [Google Scholar]
  71. MayJ. ChanC.H. KingA. WilliamsL. FrenchG.L. Time-kill studies of tea tree oils on clinical isolates.J. Antimicrob. Chemother.200045563964310.1093/jac/45.5.639 10797086
     [Google Scholar]
  72. SahuR. JainN.K. TiwariP. SinghN. DixitA. SinghG. Herbal Remedies: A new era for psoriasis diseases.Int. J. Pharm. Sci. Res.201123525
     [Google Scholar]
  73. BrownA.C. HairfieldM. RichardsD.G. McMillinD.L. MeinE.A. NelsonC.D. Medical nutrition therapy as a potential complementary treatment for psoriasis-five case reports.Altern. Med. Rev.200493297307 15387720
     [Google Scholar]
  74. MüllerK. ZiereisK. The antipsoriatic Mahonia aquifolium and its active constituents; I. Pro- and antioxidant properties and inhibition of 5-lipoxygenase.Planta Med.199460542142410.1055/s‑2006‑959523 7997469
     [Google Scholar]
  75. MišíkV. BezákováL. MálekováĽ. KošťálováD. Lipoxygenase inhibition and antioxidant properties of protoberberine and aporphine alkaloids isolated from Mahonia aquifolium.Planta Med.199561437237310.1055/s‑2006‑958107 7480190
     [Google Scholar]
  76. GulliverW.P. DonskyH.J. A report on three recent clinical trials using Mahonia aquifolium 10% topical cream and a review of the worldwide clinical experience with Mahonia aquifolium for the treatment of plaque psoriasis.Am. J. Ther.200512539840610.1097/01.mjt.0000174350.82270.da 16148424
     [Google Scholar]
  77. GalleK. Müller-JakicB. ProebstleA. JurcicK. BladtS. WagnerH. Analytical and pharmacological studies on Mahonia aquifolium.Phytomedicine199411596210.1016/S0944‑7113(11)80024‑3 23195817
     [Google Scholar]
  78. SaeleeC. ThongrakardV. TencomnaoT. Effects of Thai medicinal herb extracts with anti-psoriatic activity on the expression on NF-κB signaling biomarkers in HaCaT keratinocytes.Molecules20111653908393210.3390/molecules16053908 21555979
     [Google Scholar]
  79. ShrivastavS. SindhuR. KumarS. KumarP. Anti-psoriatic and phytochemical evaluation of thespesia populnea bark extracts.Int. J. Pharm. Pharm. Sci.200911176185
     [Google Scholar]
  80. VijayalakshmiA. RavichandiranV. VelrajM. NirmalaS. JayakumariS. Screening of flavonoid “quercetin” from the rhizome of Smilax china Linn. for anti–psoriatic activity.Asian Pac. J. Trop. Biomed.20122426927510.1016/S2221‑1691(12)60021‑5 23569912
     [Google Scholar]
  81. PalaniswamyD. NithyananthamM. RaghuP.S. DwarampudiL.P. Antipsoriatic activity and cytotoxicity of ethanolic extract of Nigella sativa seeds.Pharmacogn. Mag.201283226827210.4103/0973‑1296.103650 24082629
     [Google Scholar]
  82. DhanabalS.P. AnandR. MurugananthamN. PraveenT.K. RaghuP.S. Screening of Wrightia tinctoria Leaves for Anti-psoriatic Activity. Hygeia.J. Med.201247378
     [Google Scholar]
  83. SinghK.K. TripathyS. Natural treatment alternative for psoriasis: A review on herbal resources.J. Appl. Pharm. Sci.2014411114121
     [Google Scholar]
/content/journals/ctm/10.2174/0122150838251874231011093514
Loading
A Critical Study on the Synthetic and Herbal Medication Pattern in the Management of Psoriasis
Current Traditional Medicine 11, E241023222605 (2025); https://doi.org/10.2174/0122150838251874231011093514
/content/journals/ctm/10.2174/0122150838251874231011093514
/content/journals/ctm/10.2174/0122150838251874231011093514
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Biologicals; Capsicum frutescens; Cytokines; Herbal treatments; Methotrexate; Phototherapeutics; Psoriasis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test